Although monotherapy with either CPT‐Low or anti‐PD‐1 antibody barely achieved the apparent therapeutic effect, their combination significantly suppressed the tumor growth (Figure 2A) and prolonged the survival of tumor‐bearing mice (Figure 2B). This evidence concerns the gene PDCD1 and neoplasm.